UNITHROID (levothyroxine sodium tablets)

UNITHROID was the 1st FDA-Approved orally administered levothyroxine sodium treatment for hypothyroidism. UNITHROID tablets have been manufactured in the same facility in New York for more than 2 decades with no history of recalls, reformulations, or gaps in availability. UNITHROID is available in 12 strengths that are therapeutically equivalent to other branded synthetic levothyroxine products. In addition, with UNITHROID’s patient savings program, more than 90% of eligible commercially insured patients may pay as little as $3 for a 30-day prescription.

By delivering quality, consistency, and affordability, all in one, UNITHROID can help get your patients where they need to be no matter which way life turns.

Thyroid hormones, including UNITHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

For additional safety information or to place an order for UNITHROID samples visit UnithroidHCP.com/AAP2021.